Safety and Efficacy of UC-MSCs in Patients With Plaque Psoriasis
Phase 1
- Conditions
- Moderate and Severe Plaque Psoriasis
- Interventions
- First Posted Date
- 2018-02-07
- Last Posted Date
- 2018-04-20
- Lead Sponsor
- Tianjin Ever Union Biotechnology Co., Ltd.
- Target Recruit Count
- 57
- Registration Number
- NCT03424629
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, China
🇨🇳Tianjin Ever Union Biotechnology Co., Ltd., Beijing, China
© Copyright 2025. All Rights Reserved by MedPath